News



Abviris attracts almost 2M Euros to boost HPV cancer biomarker expansion

NEWS RELEASE Media Contact: Jennie Wilde, Carver Wilde Communications t: +44 (0) 7799 412230/ +44 (0)203 814 8445 e:   FOR IMMEDIATE RELEASE   Abviris attracts almost 2M Euros to boost HPV cancer biomarker expansion Clinical study shows efficacy of novel lateral flow test   AHRENSBURG, Germany (March 16, 2021) – Existing investors in […]

Weiterlesen »


Biotech innovator Abviris appoints new leader to drive business expansion

NEWS RELEASE Media Contact: Jennie Wilde, Carver Wilde Communications t: +44 (0) 7799 412230/ +44 (0)203 814 8445 e:   FOR IMMEDIATE RELEASE   Biotech innovator Abviris appoints new leader to drive business expansion Diagnostics industry expert Dr Roman Niedbal joins as CEO   AHRENSBURG, Germany (December 16, 2020) –Abviris Deutschland GmbH has appointed […]

Weiterlesen »


‘Pinprick’ biomarker blood test offers diagnostic potential in HPV-related cancers

NEWS RELEASE Media Contact: Jennie Wilde, Carver Wilde Communications t: +44 (0) 7799 412230/ +44 (0)203 814 8445 e:   FOR IMMEDIATE RELEASE ‘Pinprick’ biomarker blood test offers diagnostic potential in HPV-related cancers Study shows rising antibody levels predict the course of cancer AHRENSBURG, Germany (November 10, 2020) – A potential breakthrough in the […]

Weiterlesen »


AND THE WINNER IS…

Abviris Deutschland GmbH has been awarded “Pilot of the Year“ by the UK Diagnostics Summit 2019. This prestigious award was presented at the summit on 28 November 2019 in Manchester. High-ranking representatives of the National Health Service (NHS), diagnostics industry and the British IVD Association (BIVDA) honoured the results of a pilot study into the […]

Weiterlesen »


New evidence demonstrates the potential of Prevo-Check® and tumour marker DRH1® for early detection of HPV-induced diseases

Our product Prevo-Check®, a patented test for the detection of HPV16-induced tumours, is the focus of two studies to be presented at the international HPV (human papilloma virus) congress EUROGIN on December 4-7. In a study conducted at the University of Graz, Dr. Weiland and colleagues discovered that Prevo-Check® is a rapid test for identifying […]

Weiterlesen »


Investors Convinced of Potential and Importance of a Novel Cancer Management Concept

Abviris GmbH Obtains Almost 3 Million Euros in Pre-Series A Financing Abviris GmbH commenced market entry in Germany after successful test-marketing phase (450 customers, 300,000 € revenues) and, respective clinical trials. Initial positioning is targeting screening for HPV induced tumours of head and neck and the anogenital region. Funds raised in round A reveal that […]

Weiterlesen »


Tumour marker for the early detection and therapy of HPV-induced anal cancer for HIV+ patients

A pilot study has compared serum samples of HIV+ patients before and after treatment of an HPV induced anal carcinoma using the Prevo-Check®. Prevo-Check® has been confirmed as a high quality test for the early detection and therapy of HPV induced anal cancer for HIV+ patients. Study participants showing a high Prevo-Check® result developed anal […]

Weiterlesen »


Abviris and Mayo Clinic sign cooperation for research into HPV induced cancer diagnostics

Rochester, MN (USA) / Ahrensburg, Germany: Mayo Clinic and Abviris Deutschland GmbH have successfully signed a cooperation agreement for preclinical research into the diagnostics of HPV induced cancer. Mayo Clinic is one of the leading healthcare and medical research centers of the world. HPV and cancer HPV is responsible for 5% of all cancers, men […]

Weiterlesen »